Literature DB >> 33385254

In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics.

Hong Xu1, Mia O'Reilly2, Garrett S Gibbons2, Lakshmi Changolkar2, Jennifer D McBride2, Dawn M Riddle2, Bin Zhang2, Anna Stieber2, Jeffrey Nirschl2, Soo-Jung Kim2, Kevt-Her Hoxha2, Kurt R Brunden2, Gerard D Schellenberg3, John Q Trojanowski2, Virginia M-Y Lee4.   

Abstract

The microtubule-associated protein tau (tau) forms hyperphosphorylated aggregates in the brains of tauopathy patients that can be pathologically and biochemically defined as distinct tau strains. Recent studies show that these tau strains exhibit strain-specific biological activities, also referred to as pathogenicities, in the tau spreading models. Currently, the specific pathogenicity of human-derived tau strains cannot be fully recapitulated by synthetic tau preformed fibrils (pffs), which are generated from recombinant tau protein. Reproducing disease-relevant tau pathology in cell and animal models necessitates the use of human brain-derived tau seeds. However, the availability of human-derived tau is extremely limited. Generation of tau variants that can mimic the pathogenicity of human-derived tau seeds would significantly extend the scale of experimental design within the field of tauopathy research. Previous studies have demonstrated that in vitro seeding reactions can amplify the beta-sheet structure of tau protein from a minute quantity of human-derived tau. However, whether the strain-specific pathogenicities of the original, human-derived tau seeds are conserved in the amplified tau strains has yet to be experimentally validated. Here, we used biochemically enriched brain-derived tau seeds from Alzheimer's disease (AD), corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) patient brains with a modified seeding protocol to template the recruitment of recombinant 2N4R (T40) tau in vitro. We quantitatively interrogated efficacy of the amplification reactions and the pathogenic fidelity of the amplified material to the original tau seeds using recently developed sporadic tau spreading models. Our data suggest that different tau strains can be faithfully amplified in vitro from tau isolated from different tauopathy brains and that the amplified tau variants retain their strain-dependent pathogenic characteristics.

Entities:  

Keywords:  in vitro seeding; tau spreading; tau strains; tauopathy

Year:  2021        PMID: 33385254     DOI: 10.1007/s00401-020-02253-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  39 in total

1.  Differential regulation of dynein and kinesin motor proteins by tau.

Authors:  Ram Dixit; Jennifer L Ross; Yale E Goldman; Erika L F Holzbaur
Journal:  Science       Date:  2008-01-17       Impact factor: 47.728

2.  Cofactors are essential constituents of stable and seeding-active tau fibrils.

Authors:  Yann Fichou; Yanxian Lin; Jennifer N Rauch; Michael Vigers; Zhikai Zeng; Madhur Srivastava; Timothy J Keller; Jack H Freed; Kenneth S Kosik; Songi Han
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-11       Impact factor: 11.205

3.  A nucleated assembly mechanism of Alzheimer paired helical filaments.

Authors:  P Friedhoff; M von Bergen; E M Mandelkow; P Davies; E Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 4.  Molecular mechanism of Thioflavin-T binding to amyloid fibrils.

Authors:  Matthew Biancalana; Shohei Koide
Journal:  Biochim Biophys Acta       Date:  2010-04-22

5.  Signature tau neuropathology in gray and white matter of corticobasal degeneration.

Authors:  Mark S Forman; Victoria Zhukareva; Catherine Bergeron; Steven S-M Chin; Murray Grossman; Chris Clark; Virginia M-Y Lee; John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

6.  Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.

Authors:  Garrett S Gibbons; Rachel A Banks; Bumjin Kim; Lakshmi Changolkar; Dawn M Riddle; Susan N Leight; David J Irwin; John Q Trojanowski; Virginia M Y Lee
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

7.  Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules.

Authors:  Michel Goedert; Sjors H W Scheres; Benjamin Falcon; Jasenko Zivanov; Wenjuan Zhang; Alexey G Murzin; Holly J Garringer; Ruben Vidal; R Anthony Crowther; Kathy L Newell; Bernardino Ghetti
Journal:  Nature       Date:  2019-03-20       Impact factor: 49.962

8.  Structures of filaments from Pick's disease reveal a novel tau protein fold.

Authors:  Benjamin Falcon; Wenjuan Zhang; Alexey G Murzin; Garib Murshudov; Holly J Garringer; Ruben Vidal; R Anthony Crowther; Bernardino Ghetti; Sjors H W Scheres; Michel Goedert
Journal:  Nature       Date:  2018-08-29       Impact factor: 49.962

9.  Tau-Cofactor Complexes as Building Blocks of Tau Fibrils.

Authors:  Yann Fichou; Zachary R Oberholtzer; Hoang Ngo; Chi-Yuan Cheng; Timothy J Keller; Neil A Eschmann; Songi Han
Journal:  Front Neurosci       Date:  2019-12-13       Impact factor: 4.677

10.  Cryo-EM structures of tau filaments from Alzheimer's disease.

Authors:  Anthony W P Fitzpatrick; Benjamin Falcon; Shaoda He; Alexey G Murzin; Garib Murshudov; Holly J Garringer; R Anthony Crowther; Bernardino Ghetti; Michel Goedert; Sjors H W Scheres
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

View more
  9 in total

Review 1.  Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.

Authors:  Vinod Udayar; Yu Chen; Ellen Sidransky; Ravi Jagasia
Journal:  Trends Neurosci       Date:  2022-01-13       Impact factor: 13.837

Review 2.  Tau Toxicity in Neurodegeneration.

Authors:  Shu-Yu Liang; Zuo-Teng Wang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2022-03-31       Impact factor: 5.682

3.  Fluent molecular mixing of Tau isoforms in Alzheimer's disease neurofibrillary tangles.

Authors:  Aurelio J Dregni; Pu Duan; Hong Xu; Lakshmi Changolkar; Nadia El Mammeri; Virginia M-Y Lee; Mei Hong
Journal:  Nat Commun       Date:  2022-05-27       Impact factor: 17.694

4.  Inhibition of CK2 mitigates Alzheimer's tau pathology by preventing NR2B synaptic mislocalization.

Authors:  Courtney A Marshall; Jennifer D McBride; Lakshmi Changolkar; Dawn M Riddle; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol Commun       Date:  2022-03-04       Impact factor: 7.801

5.  Selective Detection of Misfolded Tau From Postmortem Alzheimer's Disease Brains.

Authors:  Ling Wu; Zerui Wang; Shradha Lad; Nailya Gilyazova; Darren T Dougharty; Madeleine Marcus; Frances Henderson; W Keith Ray; Sandra Siedlak; Jianyong Li; Richard F Helm; Xiongwei Zhu; George S Bloom; Shih-Hsiu J Wang; Wen-Quan Zou; Bin Xu
Journal:  Front Aging Neurosci       Date:  2022-07-20       Impact factor: 5.702

Review 6.  Populations of Tau Conformers Drive Prion-like Strain Effects in Alzheimer's Disease and Related Dementias.

Authors:  Lenka Hromadkova; Mohammad Khursheed Siddiqi; He Liu; Jiri G Safar
Journal:  Cells       Date:  2022-09-26       Impact factor: 7.666

Review 7.  Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.

Authors:  Aiko Robert; Michael Schöll; Thomas Vogels
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

Review 8.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.

Authors:  Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam
Journal:  J Neurochem       Date:  2021-08-06       Impact factor: 5.546

9.  Thiophene-Based Optical Ligands That Selectively Detect Aβ Pathology in Alzheimer's Disease.

Authors:  Therése Klingstedt; Hamid Shirani; Bernardino Ghetti; Ruben Vidal; K Peter R Nilsson
Journal:  Chembiochem       Date:  2021-06-21       Impact factor: 3.164

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.